Cassava Sciences settles with SEC for $40M over skewed Alzheimer’s drug data
By 
Adrianne Appel2024-09-27T18:00:00
A former Alzheimer’s researcher manipulated the results of a Cassava Sciences drug, with the pharmaceutical company and its former chief executive reaching a $40 million settlement with the Securities and Exchange Commission (SEC) over allegedly misleading the public.
Prior to 2020, researcher Hoau-Yan Wang, associate medical professor at City University of New York Medical School, embarked on a purported blind clinical trial of the experimental Alzheimer’s drug Simufilam.
Wang, who had a financial stake in the outcome of the drug trial, found out which patients had taken the drug in a third of cases and skewed the data to make the drug look dramatically more effective, the SEC alleged in it order against Wang.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
News BriefTeva Pharma to pay $450M to settle kickback, price-fixing allegations
Generic drug giant Teva Pharmaceuticals has agreed to pay $450 million to settle two cases brought by the Department of Justice (DOJ), including one alleging that co-pays it made on behalf of Medicare patients constituted illegal kickbacks, and a second action for alleged generic drug price fixing.
-
ArticleDOJ probe into shadowy underworld of short selling ‘long overdue’
A Department of Justice criminal investigation into illegal short selling is just the latest indication these schemes demand greater scrutiny that chief compliance officers and in-house counsel can no longer afford to ignore.
-
ArticleS&T AG orders Deloitte audit of short seller allegations
Austrian technology company S&T AG has ordered a forensic audit of its corporate structure and several recent acquisitions in response to allegations made by short seller Viceroy Research.
More from Regulatory Enforcement
-
ArticleFrench investigators target anticompetitive practices in largest accounting firms
Major accountancy firms in France are under investigation for anti-competitive practices. The French competition watchdog embarked on a series of “unannounced inspections” and removed documents relating to audit and reporting on Jan. 13.
-
ArticleEU investigation into Grok may expose problems with DSA rather than compliance failings
The European Commission has launched a formal investigation against Elon Musk’s X under the Digital Services Act over fears that its AI tool Grok may be producing and disseminating illegal material.
-
ArticleFormer ADM execs inflated operating profits, SEC alleges
Three former executives at Archer-Daniels-Midland intentionally misled investors by inflating the performance of the company’s Nutrition unit, the U.S. Securities and Exchange Commission has alleged.